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Abstract
Introduction: The induction of antinuclear antibodies (ANAs) or anti-double-stranded (ds) -DNA antibodies (Abs) after
infliximab (IFX) therapy in rheumatoid arthritis (RA) is a well-known phenomenon, but the correlation of such Abs with
the clinical response to IFX has not yet been determined. The aims of this retrospective observational study were to
examine the prevalence of positive ANA and anti-ds-DNA Abs before and after IFX therapy in patients with RA and to
investigate whether an increased titer of such Abs is associated with the clinical efficacy of IFX.
Methods: One hundred eleven RA patients who had received IFX were studied. ANA (indirect
immunofluorescence with HEp-2 cells) and anti-ds-DNA Abs (Farr assay) results were examined before and after IFX
therapy.
Results: The overall clinical response assessed by EULAR response criteria was as follows: good response in 55%,
including remission in 38%; moderate response in 18%; and no response (NOR) in 27%. The positivity of ANA (≥ 1:160)
and anti-ds-DNA Abs significantly increased from 25% to 40% (P = 0.03) and from 3% to 26% (P < 0.001) after IFX,
respectively. EULAR response differed significantly according to the ANA titer before IFX (P = 0.001), and the efficacy of
IFX became worse as the ANA titer before starting IFX increased. Furthermore, the differences in the clinical response of
t h eA N At i t e rb e f o r eI F X≤ 1:80 and ≥ 1:160 were significant (good, moderate, and no response were 66%, 9%, and 25%
in ≤ 1:80 group versus 26%, 33%, 41% in ≥ 1:160 group, respectively; P < 0.001). In 13 patients whose ANA had
increased after IFX, 10 showed NOR, only one showed a good response, and none reached remission. These clinical
responses were significantly different from ANA no-change patients. In 21 patients with positive anti-ds-DNA Abs after
IFX, 16 showed NOR, only two showed a good response, and none reached remission.
Conclusions: The present study suggests that the ANA titer before starting IFX predicts the clinical response to
IFX. The increased titers of ANA or anti-ds-DNA Abs after IFX may be useful markers of NOR.
Introduction
Rheumatoid arthritis (RA) is a chronic, inflammatory
disease with the potential to cause substantial joint
damage and disability. Tumor necrosis factor (TNF)-a
plays a central role in the pathogenesis of RA, as
demonstrated by the clinical benefit of anti-TNF-a
therapy [1-6]. Infliximab (IFX), a chimeric anti-human
TNF-a monoclonal antibody, has enabled great
advances in the treatment strategy for RA, resulting in a
paradigm shift of RA treatment. Although IFX therapy
concomitant with methotrexate (MTX) is effective in
the majority of RA patients, some patients have persis-
tent active disease, and others lose efficacy after pro-
longed treatment [5-7]. However, no useful clinical
marker has been established to predict such nonre-
sponse (NOR) to IFX.
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anti-double stranded (ds)-DNA antibodies (Abs) during
IFX therapy is a well-known phenomenon that has
already been observed in earlier clinical trials [1-3]. It
has been reported that the induction of ANAs is inde-
pendent of the IFX dose [2,8] and is not modified by
concomitant treatment with MTX [9,10], leflunomide,
and corticosteroid [8]. Furthermore, the production of
ANA is not associated with the clinical response to IFX
[11], and even when the development of anti-ds-DNA
Abs is observed, onset of lupus-like symptoms is extre-
mely rare [12]. Thus, the significance of the develop-
ment of such antibodies, including correlations of ANAs
and anti-ds-DNA Abs with NOR in RA, has not yet
been determined.
Recently, it was reported that the development of
ANAs and anti-ds-DNA Abs with anti-TNF therapies
may act as a marker of forthcoming treatment failure in
patients with psoriasis [13]. Conversely, as in RA
patients, it has been reported that ANAs are a predictive
factor of infusion reactions during IFX as well as with-
out MTX [14]. On the basis of these findings, the aims
of this retrospective observational study were to exam-
ine the prevalence of positive ANAs and anti-ds-DNA
Abs before and after IFX therapy in patients with RA,
and to investigate whether the induction or increased
titer of such Abs is associated with the clinical efficacy
of IFX.
Materials and methods
Patients and administration of infliximab
One hundred eleven Japanese patients with RA, who
had started using IFX as the first biologic agent from
November 2003 to June 2009 in our hospital, were stu-
died. All the patients had met the 1987 revised criteria
of the American College of Rheumatology (ACR) for the
classification of RA [15]. IFX concomitant with MTX
was given at 0 (initial dose of 3 mg/kg), 2, and 6 weeks,
and then every 8 weeks. If the efficacy of IFX was insuf-
ficient, we were permitted to increase the dosage up to
the full-bottled dose (for example, 150 mg to 200 mg in
a patient weighing 50 kg) or to shorten the administra-
tion interval up to every 6 weeks from 8 weeks, accord-
ing to the judgment of the attending physician. Disease
activity was assessed by the disease-activity score in 28
joints (DAS28 ESR) [16], and clinical responses to IFX
were evaluated with the European League against Rheu-
matism (EULAR) response criteria [17]. In contrast to
primary NOR patients who had never achieved moder-
ate or good response, loss of response (LOR) was
defined as DAS28 score returned to NOR according to
the EULAR criteria, after having maintained moderate
or good response during at least 3 times of administra-
tion of IFX. The present study was conducted in
compliance with the Declaration of Helsinki and was
approved by the Kyoto University Ethics Committee
Review Board, and written informed consent was
obtained from all patients.
Determination of study point
Determination of the study point after the IFX therapy
is different in each group. In moderate- or good-
response patients, the data were collected at a stable
point after at least three consecutive administrations of
IFX after an achievement of a moderate or good
response. In LOR patients, the data were collected
within 3 months after LOR was observed. In the IFX
withdrawal group (including primary NOR patients), the
data were collected just before IFX was discontinued.
The intervals between before and after IFX were 6 to
286 weeks (mean, 87 ± 57 weeks), and the total number
of IFX administrations was 3 to 38 times (mean, 13 ±
7.3 times), respectively.
Determination of antinuclear antibody and anti-ds-DNA
antibody
ANAs and anti-ds-DNA Abs were examined before and
after IFX therapy. ANAs were determined by indirect
immunofluorescence with HEp-2 cells, and anti-ds-DNA
Abs by the Farr assay (normal, < 6 U/ml).
Statistical analysis
Statistical analysis was performed with PAWS version 18
software, by using the Fisher Exact test for changes of
ANAs and anti-ds-DNA Abs before and after therapy,
the Jonckheere-Terpstra trend test for correlations
between ANA titers and clinical response to IFX, and
the c
2 test for comparison between two groups (includ-
ing ANA ≤ 1:80 group versus ≥ 1:160 group, and ANA
titers in the no-change group versus increased group
after therapy, respectively), respectively. A value of p <
0.05 was considered significant.
Results
Characteristics of the patients and clinical efficacy of IFX
The characteristics of 111 RA patients are shown in
Table 1: 82% were female patients; mean age was 51
years; and mean disease duration was 6.6 years at the
baseline. Mean DAS28 before IFX was 5.37, and MTX
was used in all patients at a mean dosage of 8.1 mg/
week. Corticosteroids were used in 61%, and the mean
dosage of prednisolone (PSL) was 6.2 mg/day. At the
study point, the total number of IFX administrations
was 3 to 38 times (mean, 13 times). DAS28 had fallen
to 3.55 from 5.37, and EULAR responses were as fol-
lows: good response in 55%, including remission in 38%;
moderate response in 18%; and NOR in 27%, including
LOR in 21%, respectively.
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therapy
The prevalence of positive ANA (≥ 1:40) did not change
before and after IFX (78% to 82%), but with ANA ≥
1:160, the prevalence significantly increased from 25% to
40% (Table 2; P = 0.03, Fisher Exact test). Furthermore,
the positivity of anti-ds-DNA Abs significantly increased
from 3% to 26% (P < 0.001; Fisher Exact test). The
changes of ANA titer between before and after IFX are
shown in Figure 1.
Correlation between ANA titer and clinical response to
IFX
Next, we studied the correlation between the ANA sta-
tus before starting therapy with IFX and the clinical
response to IFX. EULAR response (Figure 2(a), upper)
and DAS28 after IFX (Figure 2(a), lower) were signifi-
cantly different by ANA titer before starting IFX (P =
0.001 and 0.002, respectively, by the Jonckheere-Terp-
stra trend test), and the efficacy of IFX became worse if
the ANA titer before IFX increased. No correlation was
found between ANA titer before IFX and DAS28 before
IFX (Figure 2(a), middle). In addition, clinical responses
Table 1 Characteristics of 111 RA patients
Baseline (before starting IFX)
Female, age (mean ± SD, range) 91/111 (82%), 51.6 ± 13.3 years (21 ~ 80)
Disease duration (mean ± SD, range) 6.6 ± 6.4 years (4 months ~ 32 years)
DAS28 (ESR) (mean ± SD, range) 5.37 ± 1.33 (1.71 ~ 8.41)
MTX (mean ± SD, range) (used in all the patients), 8.1 ± 1.6 mg/week (4 ~ 14 mg)
Corticosteroids users 68/111 patients (61%)
PSL dosage (mean ± SD, range) 6.2 ± 3.2 mg/day (2 ~ 16 mg)
At the study point
Total number of IFX (mean ± SD, range) 13.0 ± 7.3 times (3 ~ 38)
DAS28(ESR) (mean ± SD, range) 3.55 ± 1.64 (0.54 ~ 7.84)
EULAR response Good response 55% (including remission 38%)
Moderate response 18%
NOR 27% (including LOR 21%)
Discontinuation 45/111 (41%)
Reasons for discontinuation Remission, eight; NOR, 21; adverse events, 14;
financial reasons, two
IFX, infliximab; LOR, loss of response; MTX, methotrexate; NOR, no response; PSL, prednisolone.
Table 2 Positivity of ANAs and anti-DNA Abs before and
after IFX
Before IFX After IFX P value
a
ANA ≥ 1:40 83/106 77/94 NS
78% 82%
≥ 1:160 27/106 38/94 0.03
25% 40%
anti-DNA ≥ 6 U/ml 3/93 21/80 < 0.001
3% 26%
ANA, antinuclear antibodies; anti-DNAs, anti-ds-DNA antibodies; IFX, infliximab;
NS, not significant.
aAnalyzed with the Fisher Exact test.
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Figure 1 Changes of ANA titer between before and after IFX.
The numbers in the graph indicate the numbers of patients. IFX,
infliximab; ANAs, antinuclear antibodies.
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titer before IFX with ≤ 1:80 and ≥ 1:160 in this figure.
As shown in Table 3, the differences in the EULAR
response between these two groups were significant (P <
0.001, c
2 test). Furthermore, when these clinical
responses to IFX were analyzed by the ANA titers after
starting IFX, such tendencies became more marked, as
s h o w ni nF i g u r e1 ( b )( P < 0.001 in both EULAR
response (upper) and DAS 28 after IFX (lower), by the
Jonckheere-Terpstra trend test). In the comparison of
the ANA titer before IFX and the EULAR response, a
significant difference in the ANA titer after IFX ≤ 1:80
and ≥ 1:160 was observed.
Clinical response of patients with increased ANA titer
after IFX
Based on these results, we next examined patients
whose ANAs had increased by two or more dilution
levels (for example, ANA titer from < 1:40 to 1:80, from
1:80 to 1:320, and so on) after treatment with IFX
(Table 4). Among these 13 patients, 10 showed NOR,
only one showed a good response, and none reached
remission. These clinical responses were significantly
different from those of the ANA no-change patients
(Table 5).
Clinical response of patients with positive anti-ds-DNA
antibodies after IFX
The characteristics of 21 patients with positive anti-ds-
DNA antibodies after IFX are shown in Table 6. Sixteen
of 21 patients showed NOR, only two showed a good
response, and none reached remission. Interestingly, the
second biologic agents, including other TNF antagonists
switched from IFX, were all effective in these patients.
Furthermore, three patients’ clinical responses to IFX
were restored by 20-mg PSL before each IFX infusion.
Discussion
In this study, we found that the high titer of ANAs (≥
1:160) significantly increased from 25% to 40% in RA
patients after using IFX, and the positivity of anti-ds-
DNA Abs was also significantly increased from 3% to
26%. These results are similar to those of previous
reports. Whereas the induction of ANAs and anti-ds-
DNA Abs during IFX therapy is a well-known phenom-
enon, the mechanisms of autoantibody production are
poorly understood, and their clinical significance is
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Figure 2 Correlation between ANA titer and clinical response
to IFX. (a) Correlations between ANAs before starting therapy with
IFX and clinical response to IFX. EULAR response (upper) and DAS28
after IFX (lower) were significantly different by ANA titer before IFX
(P = 0.001 and 0.002, respectively, by Jonckheere-Terpstra trend
test). The efficacy of IFX became worse as the ANA titer increased
before starting IFX. (b) These clinical responses to IFX were analyzed
with ANAs after starting IFX. The differences became more marked
(P < 0.001 in both EULAR response (upper) and DAS 28 after IFX
(lower), by the Jonckheere-Terpstra trend test). *Analyzed with the
Jonckheere-Terpstra trend test.
†Mean changes of DAS28 score
before and after IFX.
Table 3 Comparison of clinical response between ANA
titer ≤ 1:80 and ≥ 1:160
ANA titer
Before IFX After IFX
EULAR ≤ 1:80 ≥ 1:160 P
value
a
≤ 1:80 ≥ 1:160 P
value
a
response (n =
79)
(n =
27)
(n =
56)
(n =
38)
Good 66% 26% < 0.001 77% 11% < 0.001
(remission) (16%) (7%) < 0.001 (59%) (3%) < 0.001
Moderate 9% 33% < 0.001 7% 29% < 0.001
No 25% 41% < 0.001 16% 60% < 0.001
ANA, antinuclear antibodies; IFX, infliximab;
aAnalyzed with a c
2 test.
Table 4 Clinical response of the 13 patients with
increased ANA titer after IFX
ANA titer EULAR response
Before After
1 < 40 80 Good
2 < 40 80 No
3 < 40 640 No
4 < 40 640 No
5 40 160 No
6 40 160 No
7 40 160 Moderate
8 40 320 No
9 40 320 No
10 40 1,280 No
11 80 640 Moderate
12 160 640 No
13 320 1,280 No
ANAs, antinuclear antibodies; IFX, infliximab.
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and anti-ds-DNA Abs have been speculated on.
First, the direct effect of a decreased serum TNF level
caused by a TNF blocker is considered. It has been
reported that low levels of TNF-a may promote SLE in
predisposed mice and that the treatment of (NZB/
NZW) F1 mice with TNF-a ameliorates nephritis [18],
and low TNF-a expression may be implicated also in
human SLE patients [19]. Thus the blockade of TNF-a
itself may favor a lupus-like autoimmunity phenomenon.
Second, anti-TNF treatment also reduces CRP levels,
and CRP is known to help clear nuclear material after
apoptosis. Low CRP levels would result in the prolonged
exposure of nuclear material and hence further increase
the chance of antibody formation [20,21]; however,
serum CRP levels can be reduced not only by anti-TNF
treatment but also by other antirheumatic drugs, includ-
ing MTX and corticosteroids, and actually do not differ
between patients with and without TNF blockade
induced by autoantibodies [22]. Thus, these phenomena
alone are not sufficient to explain the production of
ANAs or anti-ds-DNA Abs. Moreover, because the
reduction of serum TNF levels is caused by etanercept
(ETN) and adalimumab (ADA), as well as IFX, it is diffi-
cult to explain the differences in the positivity of ANAs
after treatment between IFX and ETN and the success-
ful treatment of switching from IFX to ETN in patients
with positive anti-ds-DNA Abs.
As already is known, IFX inhibits not only soluble
TNF-a but also transmembrane TNF (tmTNF)-a;t h e
binding of IFX to tmTNF-a may provoke apoptotic cell
death with the expression of autoantigens that could
trigger the development of anti-ds-DNA antibodies [9].
In contrast, ETN binds mainly soluble TNF-a;t h ea b i l -
ity of IFX to bind tmTNF-a may explain why IFX but
not ETN induces the apoptosis of monocytes and T
lymphocytes in Crohn disease [23]. A recent article
demonstrated that all three anti-TNF drugs were able to
bind tmTNF-a exposed by Jurkat cells, a human
Table 5 Comparison of clinical response between ANA
titer increased and no-change patients
ANA after IFX
EULAR Increased No change P value
a
response (n = 13) (n = 76)
Good 8% 54% 0.001
(Remission) (0) (42%) 0.001
Moderate 15% 20% 0.001
No 77% 26% 0.001
ANAs, antinuclear antibodies; IFX, infliximab.
aAnalyzed with c
2 test.
Table 6 Twenty-one patients with positive anti-ds-DNA Abs after IFX
anti-DNA ANA
age/sex before after before after EULAR response symptoms IFX following biologics
1 51/F < 2 300 40 320 No Discontinue ADA- > TOC*
4
2 41/F 6 300 320 320 No Discontinue ETN
3 45/F 51 300 160 320 No SLE like*
1 Discontinue ETN
4 32/F NA 52 320 1280 No
5 31/F 5 42 80 160 No SLE like*
2 Discontinue ETN
6 36/F 5 38 40 1280 No- > good PSL 20 mg iv*
3
7 43/F 4 26 160 640 No Discontinue TOC
8 56/F 3 26 80 160 No- > good PSL 20 mg iv*
3
9 62/M 21 25 80 80 Good PCP Discontinue TOC
10 65/F 2 23 160 160 No Discontinue TOC- > ETN*
5
11 52/F NA 22 NA 160 No
12 56/M < 2 20 320 320 No allergy Discontinue ETN
13 33/F 5 19 40 80 No
14 51/F < 2 13 40 80 Mod
15 56/M < 2 11 160 160 No- > mod PSL 20 mg iv*
3
16 75/F < 2 11 < 40 320 No Discontinue ETN
17 58/F 11 11 80 640 Mod
18 30/M < 2 10 80 80 No Discontinue ETN
19 35/F < 2 10 80 80 Good
20 40/F 3 8 80 160 No Discontinue ETN
21 59/F NA 7 NA 640 Mod
anti-DNA, anti-ds-DNA antibodies; ANA, antinuclear antibodies; IFX, infliximab; SLE, systemic lupus erythematosus; PCP; pneumocystis jirovecii pneumonia; PSL,
prednisolone; iv, intravenous injection; ADA, adalimumab; ETN, etanercept; TOC, tocilizumab; *1, leukocytopenia and alopecia; *2, erythema; *3, premedication of
each IFX administration; *4, ADA was also getting no response and successful swiched to TOC; *5, TOC ineffective, and ETN effective
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dependent cell-mediated cytotoxicity; in contrast, com-
plement-dependent cytotoxicity was more pronounced
with anti-TNF-a monoclonal antibodies in comparison
with ETN [24]. These data suggest that ETN may be
less effective than both IFX and ADA in the elimination
of tmTNF-a-expressing cells. The partially different
mechanism of TNF-a inhibition between ETN and anti-
TNF-a monoclonal antibodies may explain the lesser
generation of autoantibodies in patients treated with
ETN in comparison with IFX, as well as the clinical effi-
cacy of IFX and ADA but not of ETN in the treatment
of granulomatous diseasess u c ha sC r o h nd i s e a s ea n d
Wegener granulomatosis.
Thus, some reasonable explanations exist for the pro-
duction of ANAs; however, it is unclear why their forma-
tion should be associated with the clinical response to
I F X .R e c e n t l y ,i tw a ss h o w nt h a tA N A sa r eap r e d i c t i v e
factor of infusion reactions during IFX as well as without
MTX in RA patients [14]. Furthermore, it was reported
that the development of ANA and anti-ds-DNA Abs in
anti-TNF therapies may act as a marker of forthcoming
treatment failure in patients with psoriasis [13]. To our
knowledge, the present study is the first report to clarify
the correlation of ANAs and anti-ds-DNA Abs with the
efficacy of IFX in RA patients. Moreover, surprisingly,
the clinical response to IFX differed by the ANA titer
before IFX, and the predictive value of the baseline ANA
titer of ≤ 1:80 and ≥ 1:160 for the efficacy of IFX was
observed. This result suggests that preexisting autoim-
mune abnormalities indicated by ANAs may influence
the effect of IFX. Conversely, NOR of IFX was more
markedly associated with the increase of ANAs or the
induction of anti-ds-DNA Abs. Furthermore, in NOR
patients, switching to second TNF antagonists and pre-
medication of PSL without discontinuation of IFX were
both effective, suggesting that IFX-induced autoimmune
responses may affect the efficacy of IFX.
The mechanisms underlying treatment failure in RA
patients treated with IFX have not been entirely clari-
fied; however, one important factor may be the develop-
ment of anti-drug antibody, or human anti-chimeric
antibody (HACA) [1,2]. Because these antibodies cannot
be routinely measured in the clinical setting, currently
no clinically accessible markers of forthcoming treat-
ment failure are available. Although HACA could not be
determined in all patients in this study, we could mea-
sure serum HACA in three patients who were success-
fully restored from NOR by premedication with PSL
without discontinuation of IFX, and HACA was nega-
tive, at least in these three patients.
Recently, Takeuchi et al. [7] reported that the clinical
efficacy of IFX was correlated with the trough serum IFX
level in a prospective randomized control trial (RISING
study). The authors speculated that anti-IFX antibody may
be an important factor influencing the efficacy of IFX by
increasing the serum clearance of IFX; however, anti-IFX
antibody and autoantibodies including ANAs were not
measured in the RISING study. Although the IFX trough
level was also not measured in our study, ANAs and anti-
ds-DNA Abs observed in the NOR patients in our study
seemed to be indicators of the immunologic response to
the decreased clinical efficacy of IFX. Recently, Hoffmann
et al.[ 2 5 ]r e p o r t e dt h a tA N A sa n da n t i - d s - D N AA b si n
psoriasis patients are predictors for LOR and anti-IFX
antibody induction [25], and these data strongly supported
our speculation. To confirm this speculation, a large-scale
clinical study in RA patients is necessary to examine the
correlations between the clinical efficacy of IFX and var-
ious factors, including the trough serum IFX level, anti-
IFX antibody, and autoantibodies (including ANAs and
anti-ds-DNA Abs).
One important limitation of this study was that the
approved dosage of IFX and MTX in Japan during the
study period was only 3 mg
kg every 8 weeks (IFX) and 8 mg/week (MTX),
respectively. This approved dosage of IFX and MTX in
Japan is much lower than that in Western countries,
and it may result in insufficient clinical efficacy of IFX
or suppression of immune responses to IFX. We there-
fore consider that it is necessary to research the produc-
tion of ANAs and anti-ds-DNA Abs and their
correlation with the clinical efficacy of IFX with a suffi-
cient dosage of IFX and MTX.
Recently, several prognostic markers for the efficacy of
IFX, including plasma platelet factor 4 [26] and the gene
or mRNA profile in peripheral blood cells [27,28], have
been reported; however, the measurement of these mar-
kers is complicated and commercially unavailable, and
t h ep r o g n o s t i cv a l u er e m a i n si n s u f f i c i e n t .R e g a r d i n g
these points, ANA and anti-ds DNA Abs are routine
laboratory tests and can be measured easily and simply
in daily clinical practice. In addition, IFX is the only
drug showing clinical evidence of the possibility of bio-
logics-free remission and even drug-free remission
[29,30] among the several TNF antagonists, so it is
necessary to establish prognostic markers of IFX effi-
cacy, especially clinical remission.
Conclusions
The present study suggests that the ANA titer before
starting IFX predicts the clinical response to IFX. More-
over, increased titers of ANAs or the development of
anti-ds-DNA Abs after IFX may be useful markers of
NOR. Large-scale prospective studies are required to
assess the importance of this observation.
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